Skip to main content

Table 2 Shows the clinical background of patients focusing on brain weight and scores for the mini-mental state examination (MMSE), Amyloid plaque, Tangle, Braak staging, White matter and CAA

From: APOE genotype dependent molecular abnormalities in the cerebrovasculature of Alzheimer’s disease and age-matched non-demented brains

DX APOE genotype Brain weight MMSE score Amyloid plaque score Tangle score Braak score White matter score CAA score
Control E2/E2 1207.33 ± 45.8 29 (from 1 case) 3.63 ± 2.4 3.25 ± 1.8 2.75 ± 0.3 2.5 ± 1.5 4 ± 4 (50%)
Control E2/E3. 1286 ± 48.8 28.6 ± 0.94 1.66 ± 1.1 3.54 ± 0.6 2.17 ± 0.4 2.5 ± 0.7 0 (0%)
Control E3/E3 1222 ± 34.7 28 ± 0.96 1.33 ± 1.3 2.67 ± 0.79 2.17 ± 0.4 1.67 ± 0.6 2.83 ± 1.9 (40%)
Control E3/E4 1193.75 ± 82.4 28.25 ± 0.3 3.75 ± 2.4 4.21 ± 0.9 3 ± 0.3 3.25 ± 1.9 0.4 ± 0.4 (20%)
Control E4/E4 1310 ± 40 N/A N/A N/A N/A N/A N/A
AD E2/E2 N/A N/A 7.83 ± 2.4 15 (from 1 case) 5.67 ± 0.3 6 (from 1 case) 12 (from 1 case)
AD E2/E3 1104.83 ± 80.9 18.3 ± 3.0 9.3 ± 1.7 8 ± 1.1 4.16 ± 0.2 3.3 ± 0.8 4.17 ± 1.7 (60%)
AD E3/E3 1060 ± 37.9 6.67 ± 5.7 13.04 ± 0.97 10.4 ± 2.12 4.67 ± 0.61 5.83 ± 1.9 3.4 ± 1.3 (66.6%)
AD E3/E4 1036.8 ± 49.3 18 ± 3.2 13 ± 0.6 13 ± 0.9 5.167 ± 0.3 2.8 ± 1.3 4.6 ± 0.9 (100%)
AD E4/E4 959 ± 18.1 11 ± 2 14.25 ± 0.31 14.5 ± 0.32 6 ± 0 6.2 ± 0.9 8.33 ± 1.4 (100%)